Is melanotan II approved anywhere?

No. Melanotan II is not approved by the FDA or by any comparable regulator, and it is widely sold through unregulated channels.

What does the literature report about melanotan II and moles?

The published literature includes case reports of changes to existing moles and of melanoma diagnosed in users. This page reports that those reports exist. It does not quantify a risk, because the published evidence does not support a number.

How much research exists on melanotan II?

Two hundred and forty-two PubMed records, of which seventy-four are tagged to human subjects and four are typed as clinical trials. Much of the human literature is case reports rather than trials, which is a different kind of evidence.

Melanotan II: what the evidence actually shows

Melanotan II is a synthetic analogue of alpha-melanocyte-stimulating hormone that increases melanin production in the skin.

Also known as MT-II, MT2, melanotan 2.

Evidence and regulatory status

In registered human trials. Not approved for this use.

Not approved by the FDA. Sold through unregulated channels, and the subject of published safety case reports in the dermatology literature.

Half-life

A half-life figure for Melanotan II has not been verified against a primary source for this page, so none is stated. The sources below are where a figure would come from.

What published trials used

No published human dosing trial exists for Melanotan II.

Reported for reference only. What a trial administered under supervision is not a recommendation, and Gireta does not make one.

How much research exists

PubMed records: 242
Tagged human: 74
Clinical trials: 4

A PubMed search for Melanotan II returns 242 records, of which 74 are tagged as human research and 4 are typed as a clinical trial.

Counted on 2026-09-04. Counts drift, so the exact query is linked rather than described, and you can re-run it.

Common questions

Is melanotan II approved anywhere?: No. Melanotan II is not approved by the FDA or by any comparable regulator, and it is widely sold through unregulated channels.
What does the literature report about melanotan II and moles?: The published literature includes case reports of changes to existing moles and of melanoma diagnosed in users. This page reports that those reports exist. It does not quantify a risk, because the published evidence does not support a number.
How much research exists on melanotan II?: Two hundred and forty-two PubMed records, of which seventy-four are tagged to human subjects and four are typed as clinical trials. Much of the human literature is case reports rather than trials, which is a different kind of evidence.

Sources

Alpha-MSH analogue risks · International Journal of Dermatology, via PubMed, 2017

Related compounds

Melanocortin receptor agonists

Act on melanocortin receptors, which is why pigmentation and nausea recur across the class.

Bremelanotide Bremelanotide is a melanocortin receptor agonist approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

Planning a schedule?

Gireta turns a compound and a cadence into a twelve-week timeline with the reconstitution maths worked out and a monthly cost.

Plan a Melanotan II schedule

Last reviewed 2026-09-04.